Welcome to our dedicated page for Maravai Lifesciences Holdings SEC filings (Ticker: MRVI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) SEC filings page provides access to the company’s official regulatory disclosures filed with the U.S. Securities and Exchange Commission. These documents include annual and quarterly reports, current reports on Form 8-K, and other filings that detail Maravai’s financial performance, segment results, governance changes, and material corporate events.
As a registrant on the Nasdaq Global Select Market, Maravai files periodic reports that describe its operations in two primary segments: Nucleic Acid Production and Biologics Safety Testing. In its Forms 10-K and 10-Q, investors can review revenue by segment, gross profit, operating expenses, net loss, and non-GAAP reconciliations for measures such as Adjusted EBITDA and Adjusted Net Loss. These filings also explain adjustments related to items like goodwill impairment, acquisition integration costs, stock-based compensation, restructuring charges, and other non-recurring items.
Current reports on Form 8-K are particularly important for tracking material events at Maravai. Recent 8-K filings referenced in public information cover topics such as the announcement of quarterly financial results, organizational restructuring and workforce reductions, leadership transitions including the appointment of a new Chief Executive Officer and Chief Financial Officer, and changes in the composition of the Board of Directors. These documents also describe estimated restructuring costs and the terms of executive employment and separation arrangements.
Through this page, users can follow Maravai’s regulatory history, including disclosures about its Class A common stock registered on the Nasdaq Global Select Market under the symbol MRVI and its principal location in San Diego, California. AI-powered tools on the platform can help summarize lengthy filings, highlight key sections on segment performance and restructuring, and surface information on governance changes and other events disclosed in Forms 8-K, enabling a more efficient review of Maravai’s SEC reporting.
MARAVAI LIFESCIENCES HOLDINGS, INC. officer Christine Dolan reported a routine tax-withholding transaction related to restricted stock units. On March 16, 2026, 28,661 shares of Class A common stock were withheld at $3.08 per share to cover tax obligations on vesting awards. After this non-market disposition, she directly holds 420,312 shares of Class A common stock.
Maravai Lifesciences Holdings General Counsel Kurt Oreshack reported a routine tax-withholding transaction in company stock. On the vesting of restricted stock units, 39,976 shares of Class A common stock were withheld at $3.08 per share to cover tax obligations. After this non-market disposition, he directly holds 384,991 shares of Maravai stock.
Maravai LifeSciences Holdings, Inc. reports its 2025 business overview, risk profile and strategy as a specialized life sciences supplier to drug, vaccine and diagnostics developers. The company operates through two segments: TriLink, focused on mRNA and nucleic acids, generated 64% of 2025 revenue, while Cygnus, focused on biologics safety testing, contributed 36%.
Key products include CleanCap® mRNA capping, ModTail™ poly(A) technology, custom mRNA and GMP manufacturing, and Cygnus host cell protein ELISA and MockV® viral clearance tools, backed by an extensive global patent portfolio. As of December 31, 2025, Maravai had 435 full-time employees and an aggregate non‑affiliate market value of about $300.0 million. High-volume CleanCap® sales for commercial vaccine programs fell to about 0.0% of 2025 revenue after representing 25.4% in 2024 and 21.0% in 2023, highlighting demand volatility.
In 2025 the company renamed its segments to align with its TriLink and Cygnus brands, adopted AI- and machine-learning–based design tools, and launched a Corporate Realignment Plan that includes cutting roughly 25% of the workforce and reducing facilities to lower costs and refocus on long-term growth.
Maravai LifeSciences reported fourth-quarter and full-year 2025 results showing lower revenue but improved profitability metrics in late 2025. Q4 2025 revenue was $49.9 million, down 11.8% year over year, with a net loss of $63.0 million and slightly positive Adjusted EBITDA of $0.5 million. Full-year 2025 revenue was $185.7 million, down 28.3%, with a net loss of $230.8 million and Adjusted EBITDA of $(31.2) million. TriLink revenue fell sharply due to fewer high-volume CleanCap vaccine orders, while Cygnus revenue grew modestly. For 2026, the company guides to revenue of $200–$210 million and Adjusted EBITDA of $18–$20 million, reflecting expectations for renewed growth and better margins.
Maravai LifeSciences Holdings, Inc. received an amended ownership report from 12 West Capital-related entities. 12 West Capital Management LP and its principal, Joel Ramin, report beneficial ownership of 8,921,335 shares of Class A common stock, representing 6.2% of the class.
The stake is held through 12 West Capital funds, which have rights to dividends and sale proceeds. The percentage is based on 145,022,751 Class A shares outstanding as of October 31, 2025. The filers certify the shares were not acquired to change or influence control of Maravai LifeSciences.
Maravai LifeSciences Holdings, Inc. received an updated ownership disclosure from an investor group filing an amended Schedule 13G. The group reports beneficial ownership of 10,486,451 Class A common shares, representing 7.23% of the class as of the event date.
The filing lists Hudson View entities with sole voting and dispositive power over 4,979,802 shares each, JD Squared entities with 3,000,000 shares each, and individuals including Stuart Feldman with 7,979,802 shares. The group certifies the shares were not acquired to change or influence control of Maravai.
Maravai Lifesciences Holdings, Inc. Executive Vice President & General Manager, Cygnus Technologies, Christine Dolan reported an automatic share withholding related to equity compensation. On 01/15/2026, 28,934 shares of Class A common stock were withheld at $3.69 per share to cover tax obligations arising from the vesting of restricted stock unit awards held by her. After this tax withholding event, she beneficially owned 448,973 shares of Class A common stock directly.
Maravai LifeSciences Holdings, Inc. reported a routine insider tax-withholding transaction by its General Counsel, Kurt Oreshack. On 01/15/2026, 31,902 shares of Class A common stock were withheld at a price of $3.69 per share to cover tax obligations triggered by the vesting of restricted stock units held by the insider. After this withholding, Oreshack beneficially owned 424,967 shares of Class A common stock directly. The transaction reflects share withholding for taxes rather than an open-market sale.
Maravai LifeSciences Holdings, Inc. (MRVI) reported an insider purchase by an officer of the company. On 11/14/2025, the reporting person acquired 4,300 shares of Class A Common Stock at $1.79 per share through the Maravai LifeSciences Holdings, Inc. 2020 Employee Stock Purchase Plan. The transaction was reported as exempt under Rule 16b-3. Following this purchase, the insider beneficially owns 477,907 shares of Class A Common Stock in direct ownership.
Maravai Lifesciences Holdings, Inc. (MRVI) reported an insider purchase by its Chief Executive Officer and director, Bernd Brust. On 11/13/2025, Brust, through The Bernd Brust Management Trust, purchased 216,212 shares of Class A common stock in an open-market transaction coded "P". The weighted average purchase price was $3.25 per share, with individual trade prices ranging from $3.235 to $3.25. Following this transaction, the trust beneficially owned 466,771 shares of Class A common stock held indirectly, and an additional 2,000,000 shares were listed as held directly.